Carl E Allen
Children's Oncology Group · Baylor College of Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Carl E Allen as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:07 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05828069 · A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell HistiocytosisNational Cancer Institute (NCI) · recruiting · Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis · principal investigator
- Ph2NCT04079179 · Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic DisordersCarl Allen · recruiting · Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease · study chair
- Ph2NCT03213691 · Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)National Cancer Institute (NCI) · completed · Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma · principal investigator
- Ph2NCT01858922 · Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12ABaylor College of Medicine · completed · Hodgkin Disease · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 8 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Characterization of Germline and Somatic Genetic Variants in Langerhans Cell Histiocytosis PathogenesisR03CA304855 · NCI · BAYLOR COLLEGE OF MEDICINE · fiscal years 2026 · $321,000 awarded in 2026Same name and institution; not confirmed by an ID
- PEDIATRIC ONCOLOGY CLINICAL RESEARCH TRAINING PROGRAMK12CA090433 · NCI · BAYLOR COLLEGE OF MEDICINE · fiscal years 2022 to 2026 · $640,670 awarded in 2026Same name and institution; not confirmed by an ID
- Defining Clinical Research Priorities and Strengthening Diversity and Patient-Stakeholder Engagement in Histiocytic DisordersR13TR004891 · NCATS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · fiscal years 2024 · $30,000 awarded in 2024Same name and institution; not confirmed by an ID
- Pediatric HIV/AIDS & Infection-Related Malignancies Research Consortium for sub-Saharan Africa (PARCA)U54CA254569 · NCI · BAYLOR COLLEGE OF MEDICINE · fiscal years 2020 to 2024 · $1,049,277 awarded in 2024Same name and institution; not confirmed by an ID
- AICORE-kids: Artificial Intelligence COVID-19 Risk AssEssment for kidsR33HD105593 · NICHD · BAYLOR COLLEGE OF MEDICINE · fiscal years 2023 · $1,557,070 awarded in 2023Same name and institution; not confirmed by an ID
- Molecular Epidemiology of Langerhans Cell Histiocytosis: Evaluating the Impact of SMAD6 and Genetic Ancestry on Disease RiskR01CA233719 · NCI · BAYLOR COLLEGE OF MEDICINE · fiscal years 2019 to 2023 · $586,780 awarded in 2023Same name and institution; not confirmed by an ID
- AICORE-kids: Artificial Intelligence COVID-19 Risk AssEssment for kidsR61HD105593 · NICHD · BAYLOR COLLEGE OF MEDICINE · fiscal years 2021 to 2022 · $778,430 awarded in 2022Same name and institution; not confirmed by an ID
- Redefining Langerhans Cell Histiocytosis as a Myeloid Dysplasia and Identifying BR01CA154489 · NCI · BAYLOR COLLEGE OF MEDICINE · fiscal years 2011 to 2015 · $326,398 awarded in 2015Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- COG NCTN Network Group Operations CenterU10CA180886 · NCI · COG RESEARCH FOUNDATION, LLC · PI Douglas S. Hawkins · fiscal years 2014 to 2026Named on NCT05828069, NCT03213691
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:07 UTC. The ranking covers the 200 most relevant of 8 PubMed records, and a shared surname and initials can bring in a namesake. All 8 on PubMed
- 170 citationsRCR 7.0
- Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.J Natl Cancer Inst · 201788 citationsRCR 2.4
- Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies.Blood · 201885 citationsRCR 3.5
- 53 citationsRCR 3.2
- A clinicopathologic study of the spectrum of systemic forms of EBV-associated T-cell lymphoproliferative disorders of childhood: A single tertiary care pediatric institution experience in North America.Pediatr Blood Cancer · 201926 citationsRCR 1.5
- A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis.Pediatr Blood Cancer · 201722 citationsRCR 0.7
- 18 citationsRCR 2.6
- Effect of a career decision-making course on the career planning of nursing students.J Nurs Educ · 19892 citationsRCR 0.2